Bioorthogonal Reaction of o ‐Quinone with Furan‐2( 3H )‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes
Advanced Science · 2025
DOI: 10.1002/advs.202417260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Hongfei Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Tyrosine, Furans, Immunoconjugates. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Grants Committee, Research Impact Fund, CUHK (ICSG, CRIMS, and Direct Grant).
Abstract (Originalsprache)
Bioorthogonal reactions enable the chemical conjugation of functional moieties to native proteins and empower the development of new diagnostic tools and therapeutics. Through site‐selective reactions, therapeutic molecules can be conjugated with antibodies in a stoichiometry‐ and site‐controlled manner. Here, a one‐pot chemoenzymatic reaction is reported that preferentially modifies a terminal tyrosine of recombinant proteins, or tyrosine 296 in the Fc domain of selected human antibodies. This reaction combines tyrosinase‐catalyzed oxidation of phenol to o ‐quinone, the bioorthogonal addition reaction of o ‐quinone with an azide‐containing furan‐2( 3H )‐one ( FuA ) moiety, and the subsequent azide click reactions. To this surprise, experimental evidence indicates that the o ‐quinone− FuA reaction proceeds through nucleophilic addition instead of the cycloaddition pathway. This reaction enables site‐selective modification of therapeutic human antibodies, including atezolizumab, trastuzumab, daratumumab, and cetuximab. Monofunctionalized antibody conjugates and DNA‐templated bispecific antibody complexes (DNA‐bsAbC) are thus constructed in a modular way. DNA‐bsAbC acts as a bispecific engager to mediate the interaction between immune cells and cancer cells, resulting in antibody‐dependent cellular cytotoxicity (ADCC) toward cancer cells. Taken together, here a bioorthogonal reaction is reported for site‐selective tyrosine conjugation in recombinant proteins and human antibodies and showcase its application in constructing antibody conjugates for potential applications in immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
- Department of Chemistry, Hong Kong University of Science and Technology, Kowloon, Hong Kong SAR, China.
- Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
ORCID-Profile: Jiang Xia
Förderung
- University Grants Committee
- Research Impact Fund
- CUHK (ICSG, CRIMS, and Direct Grant)
Zitieren
APA
Chen, H., Xu, Z., Bao, Y., Shiri, F., Yuan, D., Hu, Y., Li, B., Zeng, B., Li, X., Kong, H., Wang, Z., Lau, W. C., Lin, Z., & Xia, J. (2025). Bioorthogonal Reaction of o ‐Quinone with Furan‐2( 3H )‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes. Advanced Science. https://doi.org/10.1002/advs.202417260
Vancouver
Chen H, Xu Z, Bao Y, Shiri F, Yuan D, Hu Y, et al. Bioorthogonal Reaction of o ‐Quinone with Furan‐2( 3H )‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes. Advanced Science. 2025. doi:10.1002/advs.202417260
BibTeX
@article{Chen2025,
author = {Chen, Hongfei and Xu, Zhiyi and Bao, Yishu and Shiri, Farshad and Yuan, Dingdong and Hu, Yuke and Li, Biquan and Zeng, Bin and Li, Xiaojing and Kong, Hao and Wang, Zikang and Lau, Wilson Chun-Yu and Lin, Zhenyang and Xia, Jiang},
title = {Bioorthogonal Reaction of o ‐Quinone with Furan‐2( 3H )‐One for Site‐Selective Tyrosine Conjugation and Construction of Bispecific Antibody Complexes},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202417260}
}
EUVIMED